Bloodstream-delivered cell therapy slows muscle decline in young people with Duchenne musc

Bloodstream-delivered cell therapy slows muscle decline in young people with Duchenne muscular dystrophy, trial finds. A cell therapy called deramiocel could slow muscle weakening in boys and young men with advanced Duchenne muscular dystrophy (DMD) and may also slow heart damage in those who already have heart muscle disease, a Phase III clinical trial published in The Lancet has found.

A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.

Trechos de apoio da pauta: A cell therapy called deramiocel could slow muscle weakening in boys and young men with advanced Duchenne muscular dystrophy (DMD) and may also slow heart damage in those who already have heart muscle disease, a Phase III clinical trial published in The Lancet has found.

• Ponto de atenção: bloodstream.
• Ponto de atenção: delivered.
• Ponto de atenção: cell.

Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.